7 completed, 2 unknown, 1 recruiting. 4 Not applicable, 3 Phase 1, 2 Phase 4, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 2 |
| Early Phase 1 | 1 | Unknown 1 |
Follow polyethylene glycol 400: new trials by email Literature Review of polyethylene glycol 400 trials Research Report on polyethylene glycol 400
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice - Metastatic Sarcoma, Recurrent Sarcoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 20 | 2025-02-25 | 2026-08-11 |
| Systane® Hydration PF and Systane® Hydration Preserved Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF), Polyethylene glycol 400 and propylene glycol solution/drops - Preserved - Dry Eye | Not applicable | Completed | Alcon Research | 137 | 2023-10-06 | 2024-09-19 |
| Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3% - Dry Eye Disease | Not applicable | Completed | Calm Water Therapeutics LLC | 34 | 2022-12-12 | 2023-09-06 |
| Corneal Thickness Changes in Patient Undergoing Dry Eye Managment Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%, - Dry Eye Disease | Not applicable | Unknown | University of Faisalabad | 96 | 2021-07-01 | 2021-07-21 |
| Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects PRO-087, Systane Ultra, Xyel Ofteno - Dry Eye Syndromes, Lubricant Allergy | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 30 | 2017-07-17 | 2019-07-19 |
| Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV) PRO-087, Systane Ultra, Systane Ultra Preservative Free - Dry Eye Syndrome | Phase 4 | Completed | Laboratorios Sophia S.A de C.V. | 326 | 2016-10-13 | 2019-10-31 |
| Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Polyethylene Glycol, Neomycin, Metronidazole Hydrochloride - Colorectal Neoplasms, Diverticulitis | Early Phase 1 | Unknown | Thomas Jefferson University | 224 | 2016-09-01 | 2018-08-22 |
| Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision PEG-400, Systane - Myopia | Phase 4 | Completed | Bp Consulting, Inc | 40 | 2008-02-01 | 2008-11-24 |
| A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers BILR 355 BS, PEG 400 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 54 | 2002-05-01 | 2014-10-02 |
| Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects PEG 400, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 64 | 2001-09-01 | 2014-10-09 |
Dry Eye Syndromes (5) · Colorectal Neoplasms (1) · Diverticulitis (1) · Inflammatory Bowel Diseases (1) · Myopia (1) · Sarcoma (1) · Surgical Wound Infection (1)
Boehringer Ingelheim (2) · Laboratorios Sophia S.A de C.V. (2) · Alcon Research (1) · Bp Consulting, Inc (1) · Calm Water Therapeutics LLC (1) · M.D. Anderson Cancer Center (1) · Thomas Jefferson University (1) · University of Faisalabad (1)
United States (4) · Mexico (2) · Canada (1) · Pakistan (1)
Benjamin Phillips, MD (1) · Eric Donnenfeld, MD (1) · Joseph Ludwig, MD (1) · Leopoldo Baiza, MD (1) · Paul Gomes, MS (1)
R01CA180279 (1)